Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
1992-2-10
pubmed:abstractText
To develop a new approach to the treatment of advanced, hormone-refractory prostate cancer, the signal transductions regulating the growth of human androgen-independent prostate carcinoma cell lines were studied. Agonist-stimulated Ca2+ mobilization, a critical regulatory event in other secretory cell types, was studied as a means of identifying previously undescribed plasma membrane receptors that may transduce a growth inhibitory signal. In all of the cell lines tested, P2-purinergic receptor agonists, including ATP and certain hydrolysis-resistant adenine nucleotides, induced a rapid, transient increase in cytoplasmic free Ca2+ that was detectable at 50 to 100 nM ATP, was maximal at 100 microM ATP, and was inhibited approximately 50% by chelation of extracellular Ca2+. Within 8 s after addition, ATP stimulated accumulation of the polyphosphatidylinositol products inositol (1, 4, 5) trisphosphate, inositol (1, 3, 4) trisphosphate, and inositol tetrakisphosphate. In addition to stimulating phosphatidylinositol turnover and Ca2+ mobilization, ATP and hydrolysis-resistant ATP analogues induced greater than 90% inhibition of the growth of all lines tested. These data demonstrate that human androgen-independent prostate carcinoma cells express functional P2-purinergic receptors linked to phospholipase C, and that agonists of this receptor are markedly growth inhibitory, suggesting a novel therapeutic approach to this common adult neoplasm.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/1309535-1270239, http://linkedlifedata.com/resource/pubmed/commentcorrection/1309535-1707633, http://linkedlifedata.com/resource/pubmed/commentcorrection/1309535-1984806, http://linkedlifedata.com/resource/pubmed/commentcorrection/1309535-2146684, http://linkedlifedata.com/resource/pubmed/commentcorrection/1309535-2153305, http://linkedlifedata.com/resource/pubmed/commentcorrection/1309535-2171926, http://linkedlifedata.com/resource/pubmed/commentcorrection/1309535-2201533, http://linkedlifedata.com/resource/pubmed/commentcorrection/1309535-2503724, http://linkedlifedata.com/resource/pubmed/commentcorrection/1309535-2506191, http://linkedlifedata.com/resource/pubmed/commentcorrection/1309535-2506408, http://linkedlifedata.com/resource/pubmed/commentcorrection/1309535-2535674, http://linkedlifedata.com/resource/pubmed/commentcorrection/1309535-2543268, http://linkedlifedata.com/resource/pubmed/commentcorrection/1309535-2550825, http://linkedlifedata.com/resource/pubmed/commentcorrection/1309535-2813367, http://linkedlifedata.com/resource/pubmed/commentcorrection/1309535-2845374, http://linkedlifedata.com/resource/pubmed/commentcorrection/1309535-2849413, http://linkedlifedata.com/resource/pubmed/commentcorrection/1309535-2918318, http://linkedlifedata.com/resource/pubmed/commentcorrection/1309535-2922403, http://linkedlifedata.com/resource/pubmed/commentcorrection/1309535-2936872, http://linkedlifedata.com/resource/pubmed/commentcorrection/1309535-2996968, http://linkedlifedata.com/resource/pubmed/commentcorrection/1309535-3006665, http://linkedlifedata.com/resource/pubmed/commentcorrection/1309535-3010126, http://linkedlifedata.com/resource/pubmed/commentcorrection/1309535-3024320, http://linkedlifedata.com/resource/pubmed/commentcorrection/1309535-3030842, http://linkedlifedata.com/resource/pubmed/commentcorrection/1309535-3039498, http://linkedlifedata.com/resource/pubmed/commentcorrection/1309535-3140224, http://linkedlifedata.com/resource/pubmed/commentcorrection/1309535-3157927, http://linkedlifedata.com/resource/pubmed/commentcorrection/1309535-3309971, http://linkedlifedata.com/resource/pubmed/commentcorrection/1309535-3555319, http://linkedlifedata.com/resource/pubmed/commentcorrection/1309535-3838314, http://linkedlifedata.com/resource/pubmed/commentcorrection/1309535-3916740, http://linkedlifedata.com/resource/pubmed/commentcorrection/1309535-6744277, http://linkedlifedata.com/resource/pubmed/commentcorrection/1309535-6833403, http://linkedlifedata.com/resource/pubmed/commentcorrection/1309535-6871873, http://linkedlifedata.com/resource/pubmed/commentcorrection/1309535-7307008, http://linkedlifedata.com/resource/pubmed/commentcorrection/1309535-7370944
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jan
pubmed:issn
0021-9738
pubmed:author
pubmed:issnType
Print
pubmed:volume
89
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
191-6
pubmed:dateRevised
2010-9-7
pubmed:meshHeading
pubmed:year
1992
pubmed:articleTitle
P2-purinergic receptor agonists inhibit the growth of androgen-independent prostate carcinoma cells.
pubmed:affiliation
Clinical Pharmacology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't